Schroder Investment Management Group grew its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 42.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,091,675 shares of the biotechnology company’s stock after acquiring an additional 327,360 shares during the quarter. Schroder Investment Management Group owned about 2.51% of United Therapeutics Corporation worth $143,359,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of UTHR. Canada Pension Plan Investment Board increased its stake in shares of United Therapeutics Corporation by 123.8% in the 1st quarter. Canada Pension Plan Investment Board now owns 55,502 shares of the biotechnology company’s stock worth $7,514,000 after acquiring an additional 30,700 shares during the last quarter. Advisory Services Network LLC acquired a new stake in shares of United Therapeutics Corporation in the 1st quarter worth $147,000. Wedge Capital Management L L P NC increased its stake in shares of United Therapeutics Corporation by 2.7% in the 1st quarter. Wedge Capital Management L L P NC now owns 8,067 shares of the biotechnology company’s stock worth $1,092,000 after acquiring an additional 213 shares during the last quarter. State Treasurer State of Michigan increased its stake in shares of United Therapeutics Corporation by 7.0% in the 1st quarter. State Treasurer State of Michigan now owns 18,300 shares of the biotechnology company’s stock worth $2,477,000 after acquiring an additional 1,200 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System increased its stake in shares of United Therapeutics Corporation by 11.9% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 75,859 shares of the biotechnology company’s stock worth $10,270,000 after acquiring an additional 8,047 shares during the last quarter.

UTHR has been the subject of a number of recent research reports. ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 2nd. Jefferies Group LLC reaffirmed a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a research note on Thursday, June 8th. BidaskClub raised United Therapeutics Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, June 9th. UBS AG reaffirmed a “sell” rating and issued a $106.00 target price on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. Finally, Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Six analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $134.50.

United Therapeutics Corporation (UTHR) traded up 0.98% during trading on Wednesday, hitting $134.84. The stock had a trading volume of 166,491 shares. The stock’s 50-day moving average is $130.19 and its 200 day moving average is $130.88. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89. The firm has a market cap of $5.86 billion, a price-to-earnings ratio of 15.64 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by $4.86. The firm had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.42 earnings per share. Equities analysts anticipate that United Therapeutics Corporation will post $10.09 earnings per share for the current year.

In other United Therapeutics Corporation news, Director Christopher Causey sold 590 shares of the company’s stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $132.61, for a total transaction of $78,239.90. Following the completion of the sale, the director now directly owns 3,875 shares in the company, valued at $513,863.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,247 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $126.40, for a total value of $157,620.80. Following the sale, the chief executive officer now owns 2,316 shares of the company’s stock, valued at $292,742.40. The disclosure for this sale can be found here. Insiders have sold 24,606 shares of company stock valued at $3,207,882 over the last 90 days. 7.80% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Schroder Investment Management Group Buys 327,360 Shares of United Therapeutics Corporation (UTHR)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/06/schroder-investment-management-group-buys-327360-shares-of-united-therapeutics-corporation-uthr.html.

United Therapeutics Corporation Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.